Following extensive planning and preparation, Nervio launched its first US clinical trial at the Global Neurosciences Institute (GNI) together with its valued partners Prof. Sarkar Atom, of GNI and Dr. William Castro of Bromedicon/Medsurant Health.
The clinical trial is an important landmark on Nervio’s path toward FDA approval, ensuring global implementation of the groundbreaking solution.